Forma builds case for FT-4202 in competitive sickle cell space

Forma builds case for FT-4202 in competitive sickle cell space

Source: 
Fierce Biotech
snippet: 

Forma Therapeutics has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202. The high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but the safety profile offers encouragement for the ongoing phase 2/3 registrational trial.